Skip to content
Screener

Accrued Expenses at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$13.47B-22.5%
Amgen logo
AmgenAMGN
$17.19B+14.4%
Gilead Sciences logo
Gilead SciencesGILD
$3.7B+3.2%
Replimune Group logo
Replimune GroupREPL
$40.37M+9.8%
CG Oncology logo
CG OncologyCGON
$33.53M+46.0%
Precigen logo
PrecigenPGEN
$4.56M-52.6%

Other financials

Income statement

See full
Revenue$31.0K0.0%
Operating income-$16.3M-100%
Net income-$8.9M-220%
EPS (diluted)-$0.14-208%

Balance sheet

See full
Cash & equivalents$194.8M+111%
Total debt$2.8M-73.9%
Total equity$138.0M+84.8%
Total assets$201.9M+111%

Cash flow

See full
Operating cash flow-$18.0M-109%
CapEx$675.0K+22,400%
Free cash flow-$18.7M-117%

Valuation

See full
Market cap$769.34M+155%
Enterprise value$577.35M+176%

Profitability

See full
Operating margin-28,000.8%+15,050pp
Net margin-15,156.5%-5,064pp
FCF margin-26,383.9%+14,851pp

Returns & leverage

See full
Return on equity-51.2%-16.6pp
Debt / equity-0.1×
Current ratio28×+23.4×

Where this comes from

Reported directly by Candel Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.

The source filing: Candel Therapeutics, Inc.’s 10-Q, filed May 14, 2026.

Filed
May 14, 2026, 8:30 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-222904
Line itemMARCH 31,2026(Unaudited)DECEMBER 31,2025
Accounts payable$3,036$1,129
Accrued expenses3,4737,334
Current portion of lease liability453445
Other current liabilities8989
Total current liabilities7,0518,997
Deferred revenue6789
Term loan46,42846,122
Other long-term debt1,0471,008

Item 1. Financial Statements.

FAQ

What is Candel Therapeutics, Inc.'s accrued expenses?
Candel Therapeutics, Inc. (CADL) reported accrued expenses of $89K in Q1 2026.
How has Candel Therapeutics, Inc.'s accrued expenses changed year-over-year?
Candel Therapeutics, Inc.'s accrued expenses decreased by 96.7% year-over-year, from $2.72M to $89K.
What is the long-term trend for Candel Therapeutics, Inc.'s accrued expenses?
Over 5 years (2020 to 2025), Candel Therapeutics, Inc.'s accrued expenses has grown at a -13.8% compound annual growth rate (CAGR), from $187K to $89K.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.

Ask your AI about Candel Therapeutics, Inc.'s accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude